Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolaevulinic acid 20% vs. two-stage topical methyl aminolaevulinate: results of a randomized controlled trial

British Journal of Dermatology

Volumn 178, Issue 5, 2018, Pages 1056-1063

  Kessels, J P H M ^a,b,c   Kreukels, H ^d   Nelemans, P J ^e   Roozeboom, M H ^a   van Pelt, H ^f   Mosterd, K ^a,c   de Haas, E R M ^d   Kelleners Smeets, N W J ^a,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f VIECURI MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; METHYL 5-AMINOLEVULINATE; PHOTOSENSITIZING AGENT;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; ILLUMINATION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; SINGLE BLIND PROCEDURE; SUPERFICIAL BASAL CELL CARCINOMA; TOPICAL TREATMENT; TREATMENT FAILURE; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME; ULTRAVIOLET RADIATION; UNIVERSITY HOSPITAL; ADVERSE EVENT; BASAL CELL CARCINOMA; CLINICAL TRIAL; CUTANEOUS DRUG ADMINISTRATION; MIDDLE AGED; PAIN; PATIENT SATISFACTION; PHOTOCHEMOTHERAPY; PROCEDURES; SKIN TUMOR; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; PATIENT SATISFACTION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SINGLE-BLIND METHOD; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 85042631088     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15967     Document Type: Article

References (34)

1. Flohil SC, Seubring I, van Rossum MM et al. Trends in basal cell carcinoma incidence rates: a 37-year Dutch observational study. J Invest Dermatol 2013; 133:913–18.
2. Rippey JJ. Why classify basal cell carcinomas? Histopathology 1998; 32:393–8.
3. Arits AH, Mosterd K, Essers BA et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14:647–54.
4. Martin I, Schaarschmidt ML, Glocker A et al. Patient preferences for treatment of basal cell carcinoma: importance of cure and cosmetic outcome. Acta Derm Venereol 2016; 96:355–60.
5. Wang H, Xu Y, Shi J et al. Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed 2015; 31:44–53.
6. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiology B 1992; 14:275–92.
7. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003; 3:380–7.
8. Braathen LR, Szeimies RM, Basset-Seguin N et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007; 56:125–43.
9. Peng Q, Warloe T, Berg K et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79:2282–308.
10. Basset-Seguin N, Ibbotson SH, Emtestam L et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008; 18:547–53.
11. Szeimies RM, Ibbotson S, Murrell DF et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008; 22:1302–11.
12. de Haas ER, Kruijt B, Sterenborg HJ et al. Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy. J Invest Dermatol 2006; 126:2679–86.
13. Kessels J, Hendriks J, Nelemans P et al. Two-fold illumination in topical 5-aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) for superficial basal cell carcinoma (sBCC): a retrospective case series and cohort study. J Am Acad Dermatol 2016; 74:899–906.
14. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007; 1:CD003412.
15. Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications – actinic keratoses, Bowen's disease, basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27:536–44.
16. Cohen DK, Lee PK. Photodynamic therapy for non-melanoma skin cancers. Cancers (Basel) 2016; 8:E90.
17. Fritsch C, Lehmann P, Stahl W et al. Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid. Br J Cancer 1999; 79:1603–8.
18. Fritsch C, Homey B, Stahl W et al. Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem Photobiol 1998; 68:218–21.
19. Peng Q, Moan J, Warloe T et al. Build-up of esterified aminolevulinic-acid-derivative-induced porphyrin fluorescence in normal mouse skin. J Photochem Photobiol B 1996; 34:95–6.
20. Angell-Petersen E, Sorensen R, Warloe T et al. Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol 2006; 126:265–71.
21. Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. Br J Dermatol 2012; 167:733–56.
22. de Vijlder HC, Sterenborg HJ, Neumann HA et al. Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial. Acta Derm Venereol 2012; 92:641–7.
23. Robinson DJ, de Bruijn HS, de Wolf WJ et al. Topical 5-aminolevulinic acid-photodynamic therapy of hairless mouse skin using two-fold illumination schemes: PpIX fluorescence kinetics, photobleaching and biological effect. Photochem Photobiol 2000; 72:794–802.
24. Gold MH. Fractionated aminolevulinic acid-photodynamic therapy (PDT) provides additional evidence for the use of PDT for non-melanoma skin cancer. J Eur Acad Dermatol Venereol 2009; 23:571–2.
25. Peng Q, Soler AM, Warloe T et al. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B 2001; 62:140–5.
26. Sandberg C, Paoli J, Gillstedt M et al. Fluorescence diagnostics of basal cell carcinomas comparing methyl-aminolaevulinate and aminolaevulinic acid and correlation with visual clinical tumour size. Acta Derm Venereol 2011; 91:398–403.
27. Henderson BW, Fingar VH. Oxygen limitation of direct tumor cell kill during photodynamic treatment of a murine tumor model. Photochem Photobiol 1989; 49:299–304.
28. Middelburg TA, de Vijlder HC, de Bruijn HS et al. Topical photodynamic therapy using different porphyrin precursors leads to differences in vascular photosensitization and vascular damage in normal mouse skin. Photochem Photobiol 2014; 90:896–902.
29. Roozeboom MH, Nelemans PJ, Mosterd K et al. Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial. Br J Dermatol 2015; 172:739–45.
30. Vinciullo C, Elliott T, Francis D et al. Photodynamic therapy with topical methyl aminolaevulinate for ‘difficult-to-treat’ basal cell carcinoma. Br J Dermatol 2005; 152:765–72.
31. Cosgarea R, Susan M, Crisan M et al. Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27:980–4.
32. Rhodes LE, de Rie MA, Leifsdottir R et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007; 143:1131–6.
33. de Bruijn HS, de Haas ER, Hebeda KM et al. Light fractionation does not enhance the efficacy of methyl 5-aminolevulinate mediated photodynamic therapy in normal mouse skin. Photochem Photobiol Sci 2007; 6:1325–31.
34. Middelburg TA, de Bruijn HS, van der Ploeg-van den Heuvel A et al. The effect of light fractionation with a 2-h dark interval on the efficacy of topical hexyl-aminolevulinate photodynamic therapy in normal mouse skin. Photodiagnosis Photodyn Ther 2013; 10:703–9.